Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance

Core Insights - Solventum reported a 3.7% decrease in reported sales for Q4 2025, while organic sales increased by 3.5% [1] - The company provided guidance for 2026, projecting free cash flow of approximately $200 million, adjusted EPS between $6.40 and $6.60, and organic sales growth of 2.0% to 3.0% [1] Financial Performance - Q4 2025 net sales were $1.998 billion, down from $2.074 billion in Q4 2024, with a year-over-year change of -3.7% [1] - Operating cash flow for Q4 2025 was $96 million, and free cash flow was $33 million, reflecting a significant decrease from the previous year [1] - GAAP diluted EPS for Q4 2025 was $0.36, an increase of 111.8% from $0.17 in Q4 2024, while adjusted diluted EPS was $1.57, up 11.3% from $1.41 [1] Segment Performance - The Infection Prevention and Surgical Solutions segment saw a 6.2% increase in sales, while Dental Solutions grew by 8.6% [1] - Advanced Wound Care sales increased by 3.8%, and Health Information Systems grew by 4.1% [1] - The Purification and Filtration segment reported a significant decline of 29.9% due to its sale in September 2025 [1] Guidance for 2026 - The company anticipates organic sales growth of 2.0% to 3.0%, excluding an estimated 100 basis points impact from SKU exits [1] - Adjusted EPS guidance for 2026 is set between $6.40 and $6.60, indicating a focus on maintaining profitability amid market challenges [1] Cash Flow and Debt Management - The company reported a net cash provided by operating activities of $369 million for the full year 2025, down from $1.185 billion in 2024 [1] - Debt paydown following the sale of the Purification and Filtration business contributed to the increase in adjusted earnings per share [1]